Key facts
| Price (PPV) | 269 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | dapagliflozine |
| Class | Drugs used in diabetes |
| ATC code | A10BK01 |
| Manufacturer | PROMOPHARM (HIKMA) |
| Presentation | Comprimé pelliculé Boite de 30 |
| Hospital price | 179 MAD |
| Data collected on | 9/8/2026 |
Indications
Diabète de type 2 Dagliz est indiqué chez les adultes et chez les enfants de 10 ans et plus pour le traitement du diabète de type 2 insuffisamment contrôlé en complément d’un régime alimentaire et de l’exercice physique : - en monothérapie quand la metformine est considérée comme inappropriée en raison d’une intolérance. - en plus d’autres médicaments destinés au traitement du diabète de type 2. Voir rubriques 4.4, 4.5 et 5.1 pour les résultats des études concernant les associations de traitements, les effets sur le contrôle glycémique, les événements cardiovasculaires et rénaux, et les populations étudiées. Insuffisance cardiaque Dagliz est indiqué chez les adultes pour le traitement de l’insuffisance cardiaque chronique symptomatique. Maladie rénale chronique Dagliz est indiqué chez les adultes pour le traitement de la maladie rénale chronique
Find an open pharmacy
On-call pharmacies near you
Same-strength alternatives — cheapest first
Forxiga 10 mg (MAPHAR) contains the same active substance as Dagliz 10 mg (Dapagliflozine) at the same strength, but in a different pack: Boite de 28 at 419 MAD, i.e. 14.96 MAD per unit against 8.97 MAD for Dagliz 10 mg. The public sale price is set by the Ministry of Health: it is identical in every pharmacy.
| Product | Manufacturer | Pack | PPV | Unit price |
|---|---|---|---|---|
| Forxiga 10 mg | MAPHAR | Boite de 28 | 419 MAD | 14.96 / unit |
Substituting a generic is the pharmacist's decision; for medicines listed in schedules A, B and C it still requires a prescription. Public sale prices published by the Directorate of Medicines and Pharmacy, recorded on 9/8/2026.
About Dagliz 10 mg
Dagliz 10 mg belongs to the drugs used in diabetes therapeutic class. In Morocco, this drug is marketed by PROMOPHARM (HIKMA) and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Dagliz 10 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Dagliz 10 mg
Answers to common questions from Moroccan patients about this drug.